• (PLX AI) – Pharma Mar says good performance of the oncology business led to recurring revenues (sales plus royalties), growing by 7% in the first three months of the year to EUR 46 million.
  • • Q1 net income EUR 22 million
  • • Q1 EBITDA EUR 20.6 million
  • • Q1 total revenue EUR 53 million

Quelle: PLX AI